Pyrimethamine as Primary Prophylaxis of Toxoplasmic Encephalitis in Patients Infected with Human Immunodeficiency Virus: Open Study

Toxoplasmic encephalitis (TE) is one of the most frequent and life-threatening opportunistic infections in patients infected with human immunodeficiency virus (HIV). In France, 13.4% of patients with HIV infection present with TE as the first manifestation of AIDS. Its incidence among patients with...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1994-03, Vol.18 (3), p.479-480
Main Authors: Bachmeyer, Claude, Gorin, Isabelle, Deleuze, Jean, Morini, Jean-Pierre, Escande, Jean-Paul
Format: Article
Language:English
Subjects:
AIDS
AIDS-Related Opportunistic Infections - complications
AIDS-Related Opportunistic Infections - immunology
AIDS-Related Opportunistic Infections - prevention & control
Animals
Antibodies
Antibodies, Protozoan - blood
Biological and medical sciences
Cohort Studies
Correspondence
Dosage
Drug Tolerance
Encephalitis
HIV
human immunodeficiency virus
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infections
Lymphocytes
Medical sciences
Pyrimethamine - adverse effects
Pyrimethamine - pharmacology
Toxoplasma
Toxoplasma - immunology
Toxoplasmosis
Toxoplasmosis, Cerebral - complications
Toxoplasmosis, Cerebral - immunology
Toxoplasmosis, Cerebral - prevention & control
Tracheoesophageal fistula
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Toxoplasmic encephalitis (TE) is one of the most frequent and life-threatening opportunistic infections in patients infected with human immunodeficiency virus (HIV). In France, 13.4% of patients with HIV infection present with TE as the first manifestation of AIDS. Its incidence among patients with AIDS is estimated to be 30%-40%; therefore, there is a critical need for prophylaxis for TE. In our first study of TE (C. B. et al., unpublished data), we identified patients at high risk for the infection. Forty-seven (7%) of 650 patients infected with HIV-1 presenting to our institution between June 1987 and June 1991 developed TE. All patients had serum IgG antibodies to Toxoplasma at least 3 months before they developed TE and at the time of TE. IgM antibodies to Toxoplasma were not detected in the serum of any of these patients. CD4 lymphocyte counts during infection with TE were
ISSN:1058-4838
1537-6591
DOI:10.1093/clinids/18.3.479